Dermata USPTO notice of allowance for skin condition treatment patent

 

USPTO notice of allowance for skin condition treatment patent sparked premarket surge.

The U.S. Patent and Trademark Office issued Dermata Therapeutics a notice of allowance for a patent titled “COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS.” This development, reported in financial news outlets on March 19, 2026, directly boosted investor confidence in the company’s intellectual property portfolio for its dermatology programs, including its planned mid-2026 launch of an over-the-counter once-weekly acne treatment under the Tome brand. The allowance strengthens protection for the firm’s Spongilla-based technology, building on prior U.S. and Australian patents in the same family. For a small-cap biotech with limited commercial revenue, such IP milestones often catalyze sharp retail-driven moves, especially when tied to an upcoming product launch. Trading volume in premarket was notably elevated as the stock climbed approximately 25.62% from the prior close of around $1.21. No other major company-specific events (such as earnings, clinical data, or partnerships) were reported in the immediate timeframe to explain the magnitude of the move.

https://finviz.com/quote.ashx?t=DRMA&p=d